Investors are cheering an analyst's positive recommendation.
News & Analysis: Vaxart, Inc
This isn't the first time its coronavirus vaccine pill has disappointed investors.
The key is standing out from the crowd.
Can this troubled coronavirus vaccine developer redeem itself and its investors?
As with most investment decisions, whether to hold depends on the situation. Here are some things to think about.
If it can reach the market of people that are hesitant to be vaccinated, yes.
Its coronavirus vaccine candidate may stand out, if upcoming trials are successful.
Investors are excited about the company's experimental COVID-19 vaccine.
Shareholders keep getting their hopes up for the company's tablet-based COVID-19 vaccine.
The biotech is slated to provide updates to investors on its vaccine development efforts next week.